The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ELADYNOS (Theramex Australia Pty Ltd)
Product name
ELADYNOS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
150 (175 working days)
Active ingredients
abaloparatide
Registration type
NCE/ NBE
Indication
ELADYNOS is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.